The Trump administration is doing the right thing in considering a plan to allow corporations to bring back — “repatriate,” it is called — some $2.6 trillion in corporate profits that were earned overseas and left there because the companies didn’t want to pay US taxes. I advocated this repatriation a long, long time before...
NYS Entity Status
- Dissolution by Proclamation / Annulment of Authority (Dec 26, 2001)
NYS Filing Date
JULY 11, 1985
NYS DOS ID#
NYS Entity Type
DOMESTIC BUSINESS CORPORATION
1985 - BUSINESS DEVELOPMENT CORPORATION
AROUND THE WEB
- Trump’s overseas corporate tax plan is spot on
By John Crudele - Monday Aug 28, 2017
- New Development: Soft in the Middle, Splashy Up Top
By STEFANOS CHEN - Friday Sep 15, 2017
The luxury market in New York is pulling in two directions, with developers betting on big-ticket palatial aeries and million-dollar “starter” homes.
- The New Corporate Recruitment Pool: Workers in Dead-End Jobs
Sunday Sep 10, 2017
In a tight labor market, companies are looking to set up in cities with large numbers of the underemployed. In response, cities and economic-development agencies are touting this metric as a tool to lure employers.
- NY Times needs to come clean on wiretap headline
By John Crudele - Thursday Sep 7, 2017
The Justice Department announced this week that there was no evidence that Trump Tower was wiretapped, as President Trump alleged. OK, that almost settles the issue. I’m still waiting for the New York Times — the self-proclaimed “paper of record” — to explain its Jan. 20 front page story that had the headline “Wiretapped Data...
- After Sale to Accenture, Intrepid Eyes Next Chapter in Mobile Tech
By Jeff Engel - Friday Jun 30, 2017
When Mark Kasdorf started his software design and development shop, Intrepid Pursuits, in 2010, mobile apps were basically a box for businesses to check off on their corporate to-do list. “It kind of felt like everyone needed an app, and no one knew why,” Kasdorf recalls. “These people within larger companies vaguely remembered messing up” […]
- Stealthy NY Startup Rocket Pharma Merges With Inotek, Heads to Nasdaq
By Ben Fidler - Tuesday Sep 12, 2017
Rocket Pharmaceuticals, a stealthy gene therapy startup in New York City, has made its first splash. Through a merger with struggling Inotek Pharmaceuticals (NASDAQ: ITEK), Rocket, a company developing treatments for a variety of rare blood diseases, has taken itself public. Rocket shareholders are expected to own 81 percent of the combined company, with Inotek […]